Altimmune, Inc. (ALT)
$
5.24
-0.07 (-1.34%)
Key metrics
Financial statements
Free cash flow per share
-0.7422
Market cap
462.5 Million
Price to sales ratio
23.1 Thousand
Debt to equity
0
Current ratio
17.1835
Income quality
0.7907
Average inventory
0
ROE
-0.5479
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Altimmune, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for obesity and liver diseases. Its lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), acts as a GLP-1/glucagon dual receptor agonist and is currently undergoing a Phase 1b clinical trial targeting obesity and non-alcoholic steatohepatitis. Additionally, Altimmune is advancing HepTcell, an immunotherapeutic product candidate in Phase 2 trials for patients with chronic hepatitis B virus infections. The company incurred an interest expense of $9,000.00 reflecting its debt servicing obligations. The financial data pertains to the fiscal year 2024. Furthermore, the diluted EPS is -$1.34 accounting for potential share dilution, while the net income ratio stands at -4,752.95 showcasing the company's profitability margin. The operating income ratio is -5,158.60 indicating the company's operational profitability margin. Founded in 1997 and rebranded from Vaxin Inc. in September 2015, Altimmune is headquartered in Gaithersburg, Maryland. In the financial landscape, Altimmune's stock is currently affordable at $3.78 making it suitable for budget-conscious investors. The stock has a high average trading volume of 2,903,709.00 indicating robust liquidity that attracts traders. With a market capitalization of $462,468,252.00 the company is classified as a small-cap player, which often allows for significant growth potential. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Moreover, it belongs to the Healthcare sector, where it is driving innovation and growth, highlighting its role in shaping future therapies and treatments in its field.
Is Altimmune, Inc. (ALT) a good investment?
Investing in Altimmune, Inc. (ALT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Altimmune, Inc. (ALT)'s stock forecast?
Analysts predict Altimmune, Inc. stock to fluctuate between $2.90 (low) and $9.95 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Altimmune, Inc.'s market capitalization?
As of 2025-12-05, Altimmune, Inc.'s market cap is $462,468,252, based on 88,257,300 outstanding shares.
How does Altimmune, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Altimmune, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Altimmune, Inc. pay dividends?
Altimmune, Inc. pays dividends. The current dividend yield is 1,310.82%, with a payout of $291 per share.
How can I buy Altimmune, Inc. (ALT) stock?
To buy Altimmune, Inc. (ALT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALT. Place an order (Market, Limit, etc.).
What is the best time to invest in Altimmune, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Altimmune, Inc. stock ever split?
Altimmune, Inc.'s last stock split was 1:30 on 2018-09-14.
How did Altimmune, Inc. perform in the last earnings report?
Revenue: $20,000 | EPS: -$1.34 | Growth: -19.28%.
Where can I find Altimmune, Inc.'s investor relations reports?
Visit https://altimmune.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Altimmune, Inc.?
You can explore historical data from here
What is the all-time high and low for Altimmune, Inc. stock?
All-time high: $23.49 (2022-09-02) | All-time low: $2.09 (2023-10-23).
What are the key trends affecting Altimmune, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
Altimmune announces CEO transition and succession plan under which Jerry Durso will assume the role of President and Chief Executive Officer on January 1.
globenewswire.com
GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. Details are as follows:
zacks.com
The average of price targets set by Wall Street analysts indicates a potential upside of 250.6% in Altimmune (ALT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
seekingalpha.com
Altimmune, Inc. ( ALT ) Jefferies London Healthcare Conference 2025 November 20, 2025 3:00 AM EST Company Participants Vipin Garg - President, CEO & Director Christophe Arbet-Engels - Chief Medical Officer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Presentation Jiale Song Jefferies LLC, Research Division All right. Good morning, everyone, to Jefferies' London Healthcare Conference 2025.
seekingalpha.com
Altimmune remains a speculative buy as pemvidutide shows strong Phase IIb MASH results, confirmed by a recent Lancet publication. ALT's pemvidutide demonstrates significant MASH resolution, fibrosis improvement, and favorable safety, differentiating it from competitors and supporting a bullish long-term outlook. Risks include upcoming 48-week binary data, regulatory uncertainty, financial dilution, and heavy competition, but ALT's cash position reduces immediate offering risk.
globenewswire.com
24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary endpoints, including reductions in liver fat, inflammation and biomarkers of fibrosis GAITHERSBURG, Md., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced publication in The Lancet of 24-week efficacy and safety data from the ongoing IMPACT Phase 2b trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) in a paper titled “Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study”.
seekingalpha.com
Altimmune, Inc. ( ALT ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Vipin Garg - President, CEO & Director Linda Richardson - Chief Commercial Officer Gregory Weaver - Chief Financial Officer M. Roberts - Chief Scientific Officer Conference Call Participants Jiale Song - Jefferies LLC, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Patrick Trucchio - H.C.
globenewswire.com
GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for one-on-one meetings at the following investor conferences: Stifel 2025 Healthcare Conference Wednesday, November 12, 2025 Fireside Chat at 10:00 a.m.
globenewswire.com
Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option On track to complete the 24-week treatment period and announce topline results in 2026 GAITHERSBURG, Md., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the completion of patient enrollment in RECLAIM, a Phase 2 clinical trial evaluating pemvidutide in adults with alcohol use disorder (AUD).
globenewswire.com
GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it will report its third quarter 2025 financial results on Thursday, November 6, 2025.
See all news
